Dutasteride/Tamsulosin — Discount Pricing

Other medications in Urology

• Fesoterodine
• Finasteride
• Mirabegron
• Oxybutynin
• Oxybutynin Topical
• Phenazopyridine
• Phosphodiesterase 5 inhibitors
• Sildenafil

What Dutasteride/Tamsulosin is approved for (FDA label)

JALYN is a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Treatment JALYN (dutasteride and tamsulosin hydrochloride) capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.2 Limitations of Use Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer.

Source: Read the full FDA label on DailyMed. Label effective date: March 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dutasteride/Tamsulosin (FDA label)

JALYN capsules, containing 0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride, are oblong, hard-shell capsules with a brown body and an orange cap imprinted with "GS 7CZ" in black ink. 0.5 mg dutasteride and 0.4 mg tamsulosin hydrochloride. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: aab9a2d4-5328-40f3-986f-e7753a928bc0. SPL document ID: bc6c62ea-da7b-4c27-a88e-c80cfcd7856d. Label effective date: March 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dutasteride/Tamsulosin (FDA label)

The most common adverse reactions, reported in ≥1% of subjects treated with coadministered dutasteride and tamsulosin are ejaculation disorders, impotence, decreased libido, dizziness, and breast disorders. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Waylis Therapeutics LLC at 1-844-200-7910 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience The clinical efficacy and safety of coadministered dutasteride and tamsulosin, which are individual components of JALYN, have been evaluated in a multicenter, randomized, double-blind, parallel group trial (the Combination with Alpha-Blocker Therapy, or CombAT, trial).

Source: FDA prescribing information (DailyMed). Set ID: aab9a2d4-5328-40f3-986f-e7753a928bc0. SPL document ID: bc6c62ea-da7b-4c27-a88e-c80cfcd7856d. Label effective date: March 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dutasteride/Tamsulosin (FDA label)

JALYN is contraindicated for use in: Pregnancy. Dutasteride use is contraindicated in females who are pregnant. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, JALYN may cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.6) , Use in Specific Populations (8.1) ] . Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to dutasteride, other 5-alpha-reductase inhibitors, tamsulosin, or any other component of JALYN [see Adverse Reactions (6.2) ] . Pregnancy. Dutasteride use is contraindicated in females who are pregnant. ( 4 , 5.6 , 8.1 ) Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema, urticaria, pruritus, respiratory symptoms) to dutasteride, other 5-alpha-reductase inhibitors, tamsulosin, or any component of JALYN. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: aab9a2d4-5328-40f3-986f-e7753a928bc0. SPL document ID: bc6c62ea-da7b-4c27-a88e-c80cfcd7856d. Label effective date: March 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dutasteride/Tamsulosin (FDA label)

Orthostatic hypotension and/or syncope can occur. Advise patients of symptoms related to postural hypotension and to avoid situations where injury could result if syncope occurs. ( 5.1 ) Do not use JALYN with other alpha-adrenergic antagonists, as this may increase the risk of hypotension. ( 5.2 ) JALYN reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on JALYN may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. ( 5.3 ) Do not use JALYN with strong inhibitors of cytochrome P450 (CYP) 3A4 (e.g., ketoconazole).

Source: FDA prescribing information (DailyMed). Set ID: aab9a2d4-5328-40f3-986f-e7753a928bc0. SPL document ID: bc6c62ea-da7b-4c27-a88e-c80cfcd7856d. Label effective date: March 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Dutasteride/Tamsulosin (FDA label)

There have been no drug interaction trials using JALYN. The following sections reflect information available for the individual components. 7.1 Cytochrome P450 Inhibition Dutasteride Dutasteride is extensively metabolized in humans by the CYP3A4 and CYP3A5 isoenzymes. The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing a dutasteride-containing product, including JALYN, to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) [see Clinical Pharmacology (12.3) ] Tamsulosin Strong and Moderate Inhibitors of CYP3A4 or CYP2D6: Tamsulosin is extensively metabolized, mainly by CYP3A4 or CYP2D6. Concomitant treatment with ketoconazole (a strong inhibitor of CYP3A4) resulted in increases in the C max and area under the concentration-time curve (AUC) of tamsulosin by factors of 2.2 and 2.8, respectively.

Source: FDA prescribing information (DailyMed). Set ID: aab9a2d4-5328-40f3-986f-e7753a928bc0. SPL document ID: bc6c62ea-da7b-4c27-a88e-c80cfcd7856d. Label effective date: March 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.